Home » Newsletters » BioWorld Science

BioWorld Science

May 5, 2021

View Archived Issues

Enrollment opens in phase IIa study of MK-1942 in treatment-resistant depression

Aprea begins enrollment in first-in-human study of APR-548 for TP53-mutated MDS

Prime, base editing are "finer scalpels" in dystrophy

APVO-442: a bispecific T-cell engager targeting PSMA and CD3 for treating prostate cancer

Proof of concept demonstrated with ABX-002 prodrug brain delivery of thyromimetic LL-340001

Zenshine compounds targeting E-NPP 1 have antitumor activity

Vaxart initiates enrollment in phase Ib boosting regimen trial of its norovirus vaccine

Revolo presents encouraging safety data for its peptide drug for allergic disease

Incyte discloses new CDK2/cyclin E inhibitors

BeiGene synthesizes STING modulators

BioCryst Pharmaceuticals presents complement factor D inhibitors

Cellectar Biosciences describes new phospholipid-drug conjugates for cancer

First healthy volunteers dosed in phase I/II study of HDT Bio's COVID-19 RNA vaccine in India

Fate Therapeutics patents new CARs for cancer immunotherapy

Betacellulin is a novel therapeutic target in schizophrenia

Positive topline data from GENESIS phase III study of motixafortide plus G-CSF in multiple myeloma

Kiniksa reports final data from first-in-human trial of KPL-404

New mutations in the SETX gene tied to ataxia with oculomotor apraxia type 2

Ascletis reports phase IIa data on ASC-22 for chronic hepatitis B

FDA clears IND for phase I/II study of Clarity's prostate cancer theranostic products

European Commission approves Sibnayal for distal renal tubular acidosis

Preclinical characterization of novel small molecule inhibitor of CD38, RBN-013209

SOM-3355 reduces chorea in patients with HD

Tecentriq approved in E.U. for first-line metastatic NSCLC with high PD-L1 expression

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.